Figure 1.

Cdr1as Is Preferentially Downregulated in Cisplatin-Resistant Ovarian Cancer Patient Tissues

(A) circRNA microarray data of 5 paired patients, 5 with cisplatin-resistant ovarian cancer and 5 with cisplatin-sensitive ovarian cancer, are presented in a heatmap. (B) Determination of IC₅₀ values of cisplatin for both resistant cell lines after overexpression of various circRNA. (C) Relative expression of Cdr1as in cisplatin-resistant ovarian cancer and cisplatin-sensitive ovarian cancer. (D) Relative expression of Cdr1as in a panel of ovarian cancer cell lines. (E) CCK-8 assay showed that Cdr1as overexpression could dramatically inhibit the proliferation of A2780-DDP in the presence of cisplatin (20 μM). (F) CCK-8 assay showing inhibition of Cdr1as promoted the proliferation of A2780 cells in the presence of cisplatin (20 μM). All tests were performed at least three times. Data were expressed as mean ± SD. ***p < 0.001; **p < 0.01.